Ocado shares jump as profitability improves

Ocado shares jumped on Tuesday after reporting first-half results, which were cheered by investors who have become increasingly pessimistic about the company after a number of setbacks in rolling out its technology business this year.

Ocado saw group revenue rise 12.6% to £1.5bn in the first half with all business units enjoying an uptick in sales. The group’s technology solutions experienced the largest increase in revenue on a percentage basis (21.8%) while Ocado Retail added the most in monetary terms.

After what has been a tough year for Ocado shareholders, there was a glimmer of hope for the future, with profitability and cash generation metrics improving.

“It’s been a tough year for Ocado shareholders, seeing the price get slashed by half as the firm contends with the grocery market’s stuttering post-pandemic recovery and high food inflation,” said Adam Vettese, analyst at investment platform eToro.

Ocado shares were 16% at the time of writing and touched the highest point since March, making Bernstein’s downgrade yesterday to ‘underperform’ with a price target of 250p look a little premature.

Ocado’s Adjusted EBITDA rose to £71.2m from £16.6m in the same period last year. This is a notable improvement in EBITDA, but it still requires a sharp uplift to quell any questions about the company’s valuation.

Looking forward, the company was upbeat about cash generation and said it expected the group to be cash flow positive in 2026FY. It also increased its EBITDA outlook for the year. 

Many focus on Ocado’s Retail business where there was improvement in sales. However, it’s the technology business that has afforded the stock a higher multiple than retailing peers, and investors will be quietly confident today’s numbers validate the investment thesis.

“Future growth relies on its so-called Technology Solutions business, where Ocado charges third-party retailers to use its robotic systems,” said Aarin Chiekrie, equity analyst, Hargreaves Lansdown

“Hundreds of thousands of orders are processed each week with the help of its automated bots scurrying around the trademarked grid system. While this side of the business saw cash profit guidance raised, overall group growth of late hasn’t been as fast as markets had hoped. Some retail partnerships have been paused or delayed this year, denting Ocado’s growth plans and leading to certain high-profile analyst houses downgrading the stock as a result.”

Strip Tinning Holdings – Despite Recent Major Nomination Wins Near-Term Headwinds Push Back Break Into Profits – Shares Fall 25%

Adverse cost pressures, particularly in copper material price rises, which have hit the £10m capitalised Strip Tinning Holdings (LON: STG),will now materially impact revenue and profitability in the current financial year, with the company expecting FY24 and FY25 financial performance to be behind market expectations.

This morning the group has guided that it now expects that for FY 2024, revenues will be approximately £9.1m and that the adjusted EBITDA loss will be £1.9m.

The Business

Supplied in high volumes, Strip Tinning products are used by most major vehicle OEMs, with a bias towards the premium end of the market and EVs, as these vehicle types typically have more sophisticated electronic features.

Typical applications are sports and luxury cars, trucks, off-highway vehicles, new vehicle types such as autonomous shuttles, motorcycles, and even Electric Vertical Take Off and Landing (eVTOL) aircraft.

Strip Tinning has four major product groups, all serving the automotive electrical connector market – its Glazing segment is made up of Busbar and Connectors, whilst the Battery Technologies segment contains Flexible Printed Circuits (FPC) and Cell Contacting Systems (CCS).

Busbar – ultra fine gauge plated metals such as tinned copper strip to provide a circuit for electrical connections in a vehicle and Tungsten wire used for heating elements.

Connector types include cable connectors, flat foil connectors, and, increasingly, FPC connectors. These connectors provide a broad range of functionality from heated windscreens to antenna GPS / FM / TV digital signal reception and internet access, emergency response, camera and Radar / Lidar systems and “smart glass” applications for tinting, solar power generating glass, and embedded LED lighting.

FPC are circuits printed onto a flexible substrate, allowing the circuit to tolerate flexing during use as well as being thinner, lighter and simpler to install. The use of this technology is well established across all forms of electrical equipment, including in the automotive sector.

CCS, large, sophisticated electrical connectors for batteries. The CCS electrically connects the cells and provide monitoring of the cells for charge (efficiency) and temperature (safety).

The CCS can be used with battery packs for a great range of applications, including truck, off-highway, and static power applications

Currently, 90% of Strip Tinning product is exported (with the majority of the balance destined for export) to over 30 countries, including China, South Korea, Japan, Mexico, and Morocco.

Management Comments

In the April issued Report & Accounts, CEO Richard Barton had previously stated that:

“We believe that 2024 will be a formative year for the business with a strong focus on preparing for profitable delivery of the nominations already received as they ramp up in in 2025 and maintaining the investment needed to maximise our success in converting the strong Battery Technologies and Glazing sales pipeline we have before us to secure the nominations that will return us to significant growth from 2025.”

This morning Executive Chairman Adam Robson stated that:

“The two Glazing and one major Battery Technologies nominations in the first half of the year have secured our medium-term growth plans through to 2026, by which time we expect to have doubled the sales of the Company. 

In the short-term, the sector-wide headwinds we are currently facing are clearly frustrating.

That said, our nominations, extensive industry experience, ever improving productivity and strong customer relationships give us confidence in improved margins and further growth as customer confidence returns and as further new nominations are secured.”

Analyst View

Caroline de La Soujeole at Singer Capital Markets still rates the group’s shares as a Buy, but with a lower Price Objective of 65p (75p) a share.

The analyst considers that:

“For the patient investor, willing to look through short-term volatility in performance, there is a strong rationale for owning the shares given expectations of a much-improved trading performance from FY26 onwards with delivery of the Glazing & Battery Technologies order book supporting significant potential shareholder value creation.”

This morning the group’s shares have responded to the adverse news, by easing 25% to 38.50p.

FTSE 100 dips as miners drag after poor China data, Burberry sinks

The FTSE 100 was marginally lower on Monday despite the attempted assassination of Donald Trump threatening volatility in equities markets as trade got under way.

London’s leading index did fall materially in the early minutes of trade but made a respectable recovery as the session progressed and was down just 0.2% at the time of writing.

“Markets were surprisingly calm given the assassination attempt on US presidential candidate Donald Trump,” says Dan Coatsworth, investment analyst at AJ Bell.

“While equities saw a small pullback in parts of the world, there was no panic on the markets as a result of the weekend of violence.”

The biggest drag on the index stemmed from weak Chinese data released overnight that hit mining stocks heavily. Chinese GDP grew just 4.7% in the second quarter, missing analysts estimates of 5.1% and slower than growth of 5.3% in the first quarter.

“Investors are having to become accustomed to China running in second gear, a far cry from a decade ago when GDP growth was in the 7% region and when it was the envy of the world,” Coatsworth said.

“While 4.7% GDP growth is still better than many parts of the world, and certainly streets ahead of what the UK is currently managing, it is seen as failure in the context of China’s bold ambitions to be a superpower,

“Weaker economic activity has negative connotations for commodities demand, which in turn creates a less attractive backdrop for miners producing metals and minerals. That explains why Antofagasta and Anglo American were among the biggest fallers on the FTSE 100 on Monday.”

Antofagasta was down 3% and Anglo American dipped 1.7%.

Although the mining sector was the biggest drag on the index in terms of number of points, the impact of China’s luxury sector on Burberry’s sales meant the brand was by far the FTSE 100’s top faller on Monday.

Burberry shares were down over 16% at the time of writing after announcing retail revenue sank 21% in its first quarter, leading to a forecast of a first-half loss.

The Asian Pacific region, which includes China, saw retail sales plummet 23%, with Mainland Chinese sales dropping 21%. Japan was the only bright spot with sales gains of 6%.

“All of this led Burberry to suspend dividend payments, which is a desperate measure to preserve cash and fortify the balance sheet, indicating that fortunes aren’t expected to pick up in the near term,” said Aarin Chiekrie, equity analyst, Hargreaves Lansdown.

“Brand weakness extends beyond China, with Europe and the Americas also seeing double-digit revenue declines. There’s a lot of work to be done to make up for years of underinvestment in the brand. Unsurprisingly, the shares have taken a big hit in early trading. The new boss has a lot of work to do to steady the ship and prove to investors that calmer seas lie ahead.”

The dismal outlook for Burberry was compounded by another change in senior management as the CEO stepped down with immediate effect.

AIM movers: OvocaBio getting new boss and Destiny Pharma leaving AIM

0

Timothy McCutcheon will replace Kirill Golovanov as chief executive of healthcare company Ovoca Bio (LON: OVB) and he has also bought his 19.5 million shares at 0.85p each. This follows Ovoca Bio’s decision to end the development of Orenetide after disappointing trial results. The company will assess new opportunities. The share price increased 37.1% to 1.2p.

Caspian Sunrise (LON: CASP) shares have returned from suspension following publication of 2023 accounts. Average oil production fell 16% to 1,800barrels/day last year. Current aggregate production is 2,300 barrels/day from the BNG contract area, which is being sold for up to $83m. Production is expected from Block 8 and West Shalva later this year. The board will consider special dividends and share buy backs. The share price recovered 34.6% to 4.375p.

Digital services provider Silver Bullett Data Services (LON: SBDS) has secured 20 new contract wins in the first half of 2024. A global confectionery company has asked the company to take control of its data strategy. This covers revenues of £1.2m. A new $1m discounting facility will help to cover the later payment terms of larger customers. The share price is one-third higher at 100p, which is the highest level since May.

Pharmacogenetic testing company GeneDrive (LON: GDR) has received breakthrough device designation from the US FDA for the MT-RNR1 ID Kit, a rapid point of care test to screen infants for a genetic variant that can lead to hearing loss. The share price rose 35.7% to 3.8p.

FALLERS

Destiny Pharma (LON: DEST) is leaving AIM to make it easier to fund the XF-73 through access to private capital. It has been difficult to secure a commercial partner for the post-surgical infection prevention treatment. Destiny Pharma need to find funding for a phase 3 study. The share price slumped 67.7% to 2.75p.

Vast Resources (LON: VAST) raised £600,000 at 0.1p/share. Each share comes with one warrant exercisable at 0.4p. The cash will fund the reorganisation of Baita Plai to reduce production costs and to cover working capital requirements. The share price declined 34.4% to 0.105p.

Mosman Oil & Gas (LON: MSMN) produced 69,000 barrels of oil equivalent/day in the second quarter of 2024, which is 68% higher than the previous quarter. There was just over A$1m in cash at the end of June 2024. The share price dipped 17.5% to 0.066p.

Broker and acquisitions adviser Cavendish Financial (LON: CAV) had a stronger second half, which was the first period as a merged business. The figures for the year to March 2024 include Cenkos from 7 September 2024. Consolidated revenues were 46% higher at £48m. The operating loss was flat at £1.7m. The dividend is reduced from 1.15p/share to 0.25p/share. Cash was £20.7m at the end of March 2024. The trading statement is optimistic and Cavendish Financial is expected to return to profit this year. The share price fell 8.42% to 12.5p.

genedrive – ‘Point-Of-Care’ Testing Kit Gets U.S. FDA Breakthrough Device Designation Approval – Shares Up 33% 

Big news has been announced by genedrive (LON:GDR) this morning and it has got the group’s shares on the run higher – some 33% up at 3.70p in the first couple of hours trading. 

The £20m capitalised company is the Manchester-based ‘point-of-care’ pharmacogenetic testing company for use in emergency healthcare. 

Its Kits 

It is developing and commercialising a low-cost, rapid, versatile and simple to use point of need pharmacogenetic platform for the diagnosis of genetic variants. 

This helps clinicians quickly access key genetic information that will aid them make the right choices over the right medicine or dosage for an effective treatment, which is particularly important in time-critical emergency care healthcare paradigms. 

The Genedrive® MT-RNR1 ID Kit is a worlds-first and allows clinicians to decide on antibiotic use in neonatal intensive care units within 26 minutes, ensuring vital care is delivered, avoiding adverse effects potentially otherwise encountered and with no negative impact on the patient care pathway. 

Its CYP2C19 ID Kit, which has no comparably positioned competitor, currently allows clinicians to decide on the use of Clopidogrel in stroke patients in 70 minutes, ensuring that patients who are unlikely to benefit from or suffer adverse effects from Clopidogrel receive an alternative antiplatelet therapeutic promptly, ultimately improving outcomes. 

Breakthrough Device Designation By U.S. FDA 

This morning the group announced that it has received Breakthrough Device Designation from the U.S. Food and Drug Administration for the Genedrive® MT-RNR1 ID Kit. 

CEO James Cheek stated that: 

“We are delighted to receive FDA designation of our MT-RNR1 point of care pharmacogenetic test and corresponding recognition of the potential benefits to U.S. patients.   

The U.S. is an attractive market for this unique test given the potential to save hundreds of individuals from life-long deafness and reduce litigation costs relating to the unwanted side effects from antibiotic use on those carrying the gene variant, and given its size, birth rates, use of diagnostic testing and reimbursement structure.   

The FDA Breakthrough Device Designation process will be invaluable in mitigating study design risks associated with bringing a novel test such as this to the U.S. market where no predicate device exists with which to align study designs to.   

Together with our in-place partnership with a multi-state physician led clinical partner with neonatal services expertise covering the majority of U.S. states we look forward to affordable, collaborative and timely progress through the FDA De novo process.” 

Today’s news has seen a substantial increase in trading of the group’s shares, with some 82m dealt within the first two hours. 

SolGold – Shares Leap As Copper/Gold Resources Group Pulls Off Major $750m Financing For Its World-Class Cascabel Project 

This morning SolGold (LON: & TSX: SOLG) has announced that it has entered into syndication with Franco-Nevada (70%) and Osisko Bermuda (30%) to provide $750m project advancement funding for its world-class Cascabel Project in Ecuador. 

The Ecuadorian government has shown strong support for the Cascabel Project, recognising its potential to significantly boost the Ecuadorian economy. 

The Cascabel Project represents the most significant investment in Ecuador’s mining history. 

Last month the company concluded an Exploitation Contract with the government which develops the autonomy and freedom of the company to make its commercial decisions concerning technical design of the mine, investment amount, and production capacity. 

The planned mine is based on a ‘Proven and Probable’ ore reserve of ~540mt at an average grade of 0.60% copper, 0.54g/t gold and 1.6g/t silver containing 3.2mt of contained copper, 9.4moz of gold and 28moz of silver with 85% of the reserve tonnage falling within the high confidence, ‘Proven’ classification of the CIM reporting codes.  

The ore reserves are contained within 3.01bn tonnes of ‘Measured and Indicated’ resources at an average grade of 0.35% copper, 0.28g/t gold and 0.94g/t silver (reported as 0.52% on a copper equivalent basis).  

It is considered that the conversion of at least some of these resources, and the possible identification of additional resources during the mining, could trigger the need to extend the agreement beyond the initial 33-year term. 

SolGold plans to initiate the next phase of Project advancement immediately, focusing on geotechnical drilling of the tailings storage facility, additional metallurgical testing, reserves definition at the Tandayama-Ameríca deposit, hydroelectric power opportunities, plant location, and mine site design and layout, as well as securing necessary land access rights for infrastructure and commencing work on the Feasibility Study. 

On the back of this morning’s good news, the group’s shares are up 16% at 10.30p. 

Burberry shares tank after sales decline and CEO steps down, dividend suspended

British luxury fashion house Burberry shares sank on Monday after reporting a significant decline in retail revenue for the first quarter of fiscal year 2025, amidst a challenging global luxury market and internal leadership changes.

Burberry shares were down 10% at the time of writing.

The company’s retail revenue for the 13 weeks ended 29 June 2024 fell by 22% to £458 million, compared to £589 million in the same period last year. Comparable store sales declined by 21%, a stark contrast to the 18% growth seen in the previous year.

The poor performance has led to changes at the top – a familiar story for Burberry as the group grapples with its brand image and target market.

Burberry announced the immediate departure of Chief Executive Officer Jonathan Akeroyd, who will be replaced by Joshua Schulman as the new CEO and Executive Director.

“Burberry announced a change at the top by appointing Joshua Shulman as Chief Executive Officer, who has experience at Kors, Coach and Jimmy Choo. Former boss Jonathan Akeroyd has stepped down with immediate effect,” said Aarin Chiekrie, equity analyst, Hargreaves Lansdown.

“The change comes alongside a first-quarter trading update which makes tough reading for investors. Weaknesses that were already highlighted by the group coming into the financial year have worsened, with first-quarter revenue falling by an eye-watering 20%, ignoring the impact of exchange rates.”

The luxury brand faced headwinds across all key regions, with Asia Pacific experiencing a 23% drop in comparable store sales, the Americas declining by 23%, and EMEIA (Europe, Middle East, India, and Africa) falling by 16%. Only Japan showed positive growth at 6%.

Burberry has struggled with sales since the pandemic. Initially, the travel restrictions associated with COVID-19 and travel spending gave Burberry some breathing room. However, it is now clear there are deep-rooted problems at Burberry and investors acted with their feet and jumped out of the stock on Monday.

Burberry warned that if current trading trends continue, it expects to report an operating loss for the first half of FY25 and full-year operating profit below current consensus. As a precautionary measure, the company has decided to suspend dividend payments for FY25 to maintain a strong balance sheet and invest in long-term growth.

For the full fiscal year 2025, Burberry anticipates wholesale revenue to decline by around 30%, with capital expenditure projected at approximately £150 million. The company also expects a currency headwind of about £55 million to revenue and £20 million to operating profit.

New AIM admission: Don’t ignore potential dilution at Rosebank Industries

Rosebank Industries shares have gone to a huge premium in their first two days of trading on AIM, but investors should remember that there is potential dilution from incentive shares.

Founders and management of Melrose Industries, one of the three former AIM companies that are constituents of the FTSE 100 index, have set up the investment vehicle to acquire an industrial business. Any acquisition could be worth more than £2bn in debt and shares.

There are A series and B series incentive shares in issue and there are plans to issue C series incentive shares. Each series is entitled to re...

Aquis new admission: Smarter manufacturing with IntelliAM AI

IntelliAM AI is developing AI technology to enable more efficient manufacturing practices. It has acquired a consulting business with a client base that could provide further opportunities for the technology.

Since flotation, IntelliAM AI secured a funding award of £263,000 from DIF Lighthouse Fund. This is for research into the application of AI in lubrication analysis. A machine learning model will be created.

Cash raised will fund further technology development. The share price has risen to 110p. There has been limited liquidity since the first day of trading. Fairly valued for now.
...

Aquis weekly movers: Oscillate plans hydrogen deal

Oscillate (LON: MUSH) has entered into non-binding heads of terms for the acquisition of Quantum Hydrogen Inc. The bid target has exploration rights over 60,000 acres in the state of Minnesota. There is a 60-day due diligence period. Richard and Charlott Edwards have reduced their stake in Oscillate from 8.31% to 7.6%. The share price increased 36% to 0.85p. That is the highest level for nearly two years.

Quantum Exponential Group (LON: QBIT) is still talking to a potential investor and there have been indications of interest from others. These discussions have been going on for weeks, but management believes that they have potential for a positive conclusion. The share price is 11.1% higher at 0.5p.

Tap Global Group (LON: TAP) chief executive Arsen Torosian bought 12.25 million shares at 0.5p each. The share price improved 6.25% to 0.85p.

Software developer IntelliAM (LON: INT) has secured a funding award of £263,000 from DIF Lighthouse Fund. This is for research into the application of AI in lubrication analysis. A machine learning model will be created. Gresham House Asset Management holds 23.5% of the company. The share price rose 4% to 65p.

Shepherd Neame (LON: SHEP) non-executive director George Barnes bought 1,000 shares at 666p each. The share price moved up 1.13% to 672.5p.

FALLERS

Gunsynd (LON: GUN) has decided to leave Aquis and it plans to acquire a 100% stake in the Falcon Lake uranium, copper and cobalt project and the Bear-Twit VMS project in Canada. The consideration is £200,000 in shares and cash. It will also commit £100,000 to work programmes. The last day of dealings on Aquis will be 9 August. The share price dipped 3.7% to 0.13p.

Shortwave Life Sciences (LON: PSY) has received a positive response from the PCT examining authority acknowledging its patent claims for its drug delivery platform for psychedelic-based drugs. More than nine million shares have been issued as deferred consideration for the acquisition of Shortwave Pharma Inc. The share price fell 2.58% to 1.51p.

Skin treatments developer Incanthera (LON: INC) has received a second Skin + CELL production order of 250,000 units from Marionnaud AG. This will be delivered before the end of March 2025. Total projected revenues for both orders are more than £10m. The share price lost 1.75% to 28p, but it is still more than quadruple the level at the start of the year.